EUVIMEDEUVIMED entdecken
Crossref

Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B

Tyng-Yuan Jang iD, Chih-Wen Wang iD, Po-Cheng Liang, Yu-Ju Wei, Ming-Lun Yeh iD, Yi-Hung Lin, Chao-Kuan Huang, Pei-Chien Tsai, Yu-Min Ko, Yi-Shan Tsai, Kuan-Yu Chen, Ching-Chih Lin und 6 weitere

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.70021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Tyng-Yuan Jang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Kaohsiung Medical University, Kaohsiung Medical University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims We aimed to investigate the association between steatotic liver disease‐related genetic risk and hepatocellular carcinoma (HCC) in Taiwanese patients with chronic hepatitis B (CHB) treated with nucleotide/nucleoside analogs (NAs).

Methods

We enrolled 745 Taiwanese patients with CHB treated with NAs and analyzed the incidence and risk factors for HCC. Steatotic liver disease (SLD)–related single nucleotide polymorphisms (SNPs) were tested, and a polygenetic risk score (PRS) for hepatocellular carcinoma was created.

Results

The annual incidence of HCC was 1.7/100 person‐years after a follow‐up of > 3346.9 person‐years. Factors with the strongest association with HCC were liver cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 4.51/2.12–9.62; p < 0.001), followed by male sex (4.20/1.64–10.79; p = 0.003), a sSLD‐related PRS > 0.062 (2.24/1.09–4.58; p = 0.03), body mass index (BMI) (1.15/1.07–1.24; p < 0.001), and age (1.06/1.03–1.10; p < 0.001). Among patients without cirrhosis, the HCC‐associated factors were male sex (HR/CI: 1.17/1.10–1.24; p < 0.001) and BMI (1.16/1.03–1.30; p = 0.01). In contrast, a high PRS (HR/CI: 2.57/1.19–5.57; p = 0.02) was the only HCC‐associated factor in patients with cirrhosis.

Conclusions

The SLD‐related gPRS predicted HCC development in CHB patients treated with NAs. The genetic effects were particularly enhanced in patients with cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis B, ChronicPolymorphism, Single NucleotideFatty LiverNucleotidesNucleosidesAntiviral AgentsHumansMaleFemaleMiddle AgedRisk FactorsTaiwanAdultIncidenceLiver CirrhosisRisk Assessment

Stichwörter der Autor:innen

HBVHCCNAsNUCPRSSLDSNP

Substanzen

NucleotidesNucleosidesAntiviral Agents

Autor:innen und Institutionen

  • Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare, Pingtung City, Taiwan.
  • Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Faculty of Internal Medicine and Hepatitis Research Center, School of Medicine, College of Medicine, and Center for Cancer Research and Liquid Biopsy, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Center From Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Pharmacy and Master Program, College of Pharmacy and Health Care, Tajen University, Pingtung City, Taiwan.

ORCID-Profile: Tyng-Yuan Jang, Chih-Wen Wang, Ming-Lun Yeh, Jee-Fu Huang, Chia-Yen Dai, Chung-Feng Huang, Ming-Lung Yu

Förderung

  • Kaohsiung Medical University
  • Kaohsiung Medical University Hospital
  • Kaohsiung Medical University Chung-Ho Memorial Hospital

Zitieren

APA

Jang, T. Y., Wang, C. W., Liang, P. C., Wei, Y. J., Yeh, M. L., Lin, Y. H., Huang, C. K., Tsai, P. C., Ko, Y. M., Tsai, Y. S., Chen, K. Y., Lin, C. C., Lin, Z. Y., Huang, J. F., Dai, C. Y., Huang, C. F., Chuang, W. L., & Yu, M. L. (2025). Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70021

Vancouver

Jang TY, Wang CW, Liang PC, Wei YJ, Yeh ML, Lin YH, et al. Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.70021

BibTeX
@article{Jang2025,
  author = {Jang, Tyng-Yuan and Wang, Chih-Wen and Liang, Po-Cheng and Wei, Yu-Ju and Yeh, Ming-Lun and Lin, Yi-Hung and Huang, Chao-Kuan and Tsai, Pei-Chien and Ko, Yu-Min and Tsai, Yi-Shan and Chen, Kuan-Yu and Lin, Ching-Chih and Lin, Zu-Yau and Huang, Jee-Fu and Dai, Chia-Yen and Huang, Chung-Feng and Chuang, Wan-Long and Yu, Ming-Lung},
  title = {Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.70021}
}
Kostenlos starten →